Employee of French drugmaker Ipsen to plead guilty to US insider trading
Adds defense lawyer comment in paragraph 3
By Nate Raymond
BOSTON, Sept 10 (Reuters) -An employee of French drugmaker Ipsen IPN.PA has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug developer Epizyme in 2022.
Dishant Gupta, Ipsen's director of data strategy and operations, plans to plead guilty to securities fraud and is settling related claims by the U.S. Securities and Exchange Commission, according to filings in Boston federal court on Tuesday.
A plea hearing is set for Oct. 8.Jeffrey Lichtman, a lawyer for the 40-year-old New Jersey resident, in an email said his client was working to resolve the case.
Ipsen said it does not comment on legal matters concerning current or former employees and was focused on compliance with applicable laws.
Prosecutors said that an Ipsen executive during a meeting in Cambridge, Massachusetts, in March 2022 asked Gupta to help him put together materials related to a potential acquisition of a cancer drug and an unidentified drug company's assets.
Days later, he met with Ipsen executives to discuss possible acquisitions in the oncology market, and by April 7, 2022, Gupta knew the cancer drug and assets Ipsen wanted to acquire belonged to Cambridge-based biotech Epizyme, the maker of the cancer medication Tazverik, prosecutors said.
That day, he began buying Epizyme shares in his wife's brokerage account, according to charging documents. He bought more in the days that followed as the companies discussed a potential outright acquisition of Epizyme, prosecutors said.
Gupta began conducting frequent internet searches that authorities said showed his awareness of a potential deal, with searches for "Epizyme buyout" and "Epizyme takeover," according to prosecutors and the SEC.
Ipsen announced its $247 million acquisition of Epizyme on June 27, 2022. Gupta then sold all of his Epizyme shares, netting him a profit of more than $262,000, prosecutors said.
Reporting by Nate Raymond in Boston
Editing by Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
